PharmaCyte Biotech, Inc.

PMCB

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001157075

SEC filings (opens in a new tab)

No open-market purchases or sales by PharmaCyte Biotech, Inc. insiders were filed in the last 90 days; 32 institutions reported holding it in 13F filings for Q2 2026, worth $586.2K in total; no superinvestor holds it.

Q1 2024 vs. Q4 2023

How the institutions holding PharmaCyte Biotech, Inc. changed between Q4 2023 and Q1 2024.

All holders in Q1 2024 All holders in Q4 2023

13F holders of PMCB: Q4 2023 compared with Q1 2024
Measure	Q4 2023	Q1 2024	Change
Holders	36	33	−3
Shares	1.09M	978.3K	−110.3K (−10.1%)
Value	$2.35M	$2.32M	−$28.6K (−1.2%)

New holders (1)

Institutions that held PharmaCyte Biotech, Inc. at the end of Q1 2024 but not at the end of Q4 2023.

Institutions new to PMCB in Q1 2024
Institution	Shares	Value	% of portfolio
BFSG, LLC	7	$17	0.00%

Sold out (4)

Institutions that held PharmaCyte Biotech, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.

Institutions that sold out of PMCB in Q1 2024
Institution	Shares, Q4 2023	Value, Q4 2023
Sabby Management, LLC	82,373	$177.9K
Bank of New York Mellon Corp	16,598	$35.9K
Squarepoint Ops LLC	14,846	$32.1K
Northwestern Mutual Wealth Management Co	14	$30